Kindred Biosciences (KIN) Insider Richard Chin Sells 1,930 Shares of Stock

Kindred Biosciences (NASDAQ:KIN) insider Richard Chin sold 1,930 shares of the firm’s stock in a transaction on Wednesday, May 9th. The stock was sold at an average price of $10.01, for a total value of $19,319.30. Following the sale, the insider now directly owns 2,244,341 shares in the company, valued at approximately $22,465,853.41. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Richard Chin also recently made the following trade(s):

Get Kindred Biosciences alerts:

On Monday, May 7th, Richard Chin sold 1,730 shares of Kindred Biosciences stock. The stock was sold at an average price of $10.01, for a total value of $17,317.30. On Tuesday, May 1st, Richard Chin sold 20,000 shares of Kindred Biosciences stock. The stock was sold at an average price of $9.05, for a total value of $181,000.00. On Monday, April 2nd, Richard Chin sold 20,000 shares of Kindred Biosciences stock. The stock was sold at an average price of $8.39, for a total value of $167,800.00.

Shares of KIN traded down $0.05 during midday trading on Thursday, hitting $9.60. The stock had a trading volume of 14,994 shares, compared to its average volume of 110,833. Kindred Biosciences has a twelve month low of $9.45 and a twelve month high of $9.90. The company has a market capitalization of $273.57 million, a price-to-earnings ratio of -7.80 and a beta of 0.08.

Kindred Biosciences (NASDAQ:KIN) last released its quarterly earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.36). research analysts expect that Kindred Biosciences will post -1.5 EPS for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Schwab Charles Investment Management Inc. raised its stake in shares of Kindred Biosciences by 18.6% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 42,100 shares of the biopharmaceutical company’s stock valued at $398,000 after purchasing an additional 6,600 shares during the period. BlackRock Inc. raised its stake in shares of Kindred Biosciences by 4.0% in the 4th quarter. BlackRock Inc. now owns 1,115,709 shares of the biopharmaceutical company’s stock valued at $10,544,000 after purchasing an additional 42,777 shares during the period. Wells Fargo & Company MN raised its stake in shares of Kindred Biosciences by 2.2% in the 3rd quarter. Wells Fargo & Company MN now owns 337,608 shares of the biopharmaceutical company’s stock valued at $2,650,000 after purchasing an additional 7,206 shares during the period. B. Riley Financial Inc. acquired a new stake in shares of Kindred Biosciences in the 1st quarter valued at about $1,120,000. Finally, Bank of New York Mellon Corp raised its stake in shares of Kindred Biosciences by 12.1% in the 4th quarter. Bank of New York Mellon Corp now owns 83,543 shares of the biopharmaceutical company’s stock valued at $789,000 after purchasing an additional 8,995 shares during the period. 64.22% of the stock is currently owned by hedge funds and other institutional investors.

Several brokerages recently commented on KIN. Zacks Investment Research raised Kindred Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, May 5th. BidaskClub raised Kindred Biosciences from a “hold” rating to a “buy” rating in a research note on Saturday, April 14th. HC Wainwright raised their price objective on Kindred Biosciences to $12.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, ValuEngine raised Kindred Biosciences from a “hold” rating to a “buy” rating in a research note on Tuesday, April 17th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $9.96.

About Kindred Biosciences

Kindred Biosciences, Inc, a biopharmaceutical company, focuses on the development of therapies for pets. The company's product pipeline includes small molecules and biologics for a range of indications in dogs, cats, and horses. Its lead product candidates comprise Zimeta, a dipyrone injection for the control of pyrexia (fever) in horses; and Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.

Insider Buying and Selling by Quarter for Kindred Biosciences (NASDAQ:KIN)

Leave a Reply

Your email address will not be published. Required fields are marked *